Comparing platelet rich plasma and corticosteroids for hip osteoarthritis pain relief
The Efficacy of Platelet Rich Plasma Compared With Corticosteroid Injections for the Treatment of Pain Associated With Hip Osteoarthritis
This study is testing whether platelet rich plasma injections work better than corticosteroid injections to relieve pain and improve function in people with hip osteoarthritis.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 54 (estimated) |
| Ages | 21 Years to 80 Years |
| Sex | All |
| Sponsor | LifeBridge Health Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06793982 on ClinicalTrials.gov |
What this trial studies
This is a prospective, single-center randomized trial that aims to compare the effectiveness of platelet rich plasma (PRP) injections versus corticosteroid injections in alleviating pain and improving function in patients with hip osteoarthritis. The study will assess patient-reported outcomes to determine which treatment offers superior relief. Participants will be randomly assigned to receive either PRP or corticosteroid injections, and their progress will be monitored throughout the study duration.
Who should consider this trial
Good fit: Ideal candidates are males and females aged 21-80 with a radiographic diagnosis of Kellgren-Lawrence grade II or III hip osteoarthritis who require an injection for symptom relief.
Not a fit: Patients with chronic pain conditions, recent hip injections, or those with diabetes mellitus may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide patients with a more effective treatment option for managing hip osteoarthritis pain.
How similar studies have performed: While there is limited evidence comparing these two treatments in a randomized manner, the use of platelet rich plasma has shown promise in other studies, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 21-80 years * Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hip osteoarthritis * Indicated for a Hip injection to treat Hip OA symptoms Exclusion Criteria: * Any injections into the target Hip within three months * Current overlying skin infection * Current or previous diagnosis of "chronic pain" * Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.) * Allergy to any potential ingredients or medications utilized in any of the two groups * Treatment with another investigational drug or other intervention for pain * Diagnosis of Diabetes Mellitus * If female, pregnant or planning to be pregnant within the following 3 months or study duration * Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation
Where this trial is running
Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Study coordinator: Martin Gesheff, DHSc
- Email: mgesheff@lifebridgehealth.org
- Phone: 410-601-9467
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.